Objective: Thrombocytopenia is a significant and morbid problem in patients with hematologic malignancy, resulting in frequent platelet transfusions and significant resource consumption. We undertook this study to determine the impact of splenectomy on transfusion requirements in patients with chronic leukemia, acute leukemia, myelodysplastic syndrome, and lymphoma. Methods: Records of 134 patients with hematologic malignancies who underwent splenectomy were reviewed. Results are reported as mean Ϯ standard error of the mean. Results: Mean preoperative (preop) platelet count was 97 Ϯ 8 K/L. A significant rise in platelets, compared with preop, was observed starting on postsplenectomy day 1 (141 Ϯ 8 K/L, P Ͻ 0.001 versus preop) and persisted through day 7. Counts remained significantly elevated at 3 and 6 months and years 1-5. In profoundly thrombocytopenic patients (preop levels Ͻ 20 K/L), preop count was 11 Ϯ 1 K/L. A significant postsplenectomy platelet rise persisted for at least 1 year (137 Ϯ 52 K/L, P Ͻ 0.05 versus preop). An increased platelet level was observed in all hematologic subgroups; in the chronic leukemias (n ϭ 58, P Ͻ 0.01) and in lymphoma (n ϭ 59, P Ͻ 0.001), this reached significance. Mean platelet transfusions were significantly decreased from preop (3 months preop: 8.6 Ϯ 2 units) compared with postsplenectomy (3 months postsplenectomy: 5.0 Ϯ 1 unit, P ϭ 0.03). This decrease was even more pronounced in profoundly thrombocytopenic patients (31.6 Ϯ 10.6 units preop versus 8.9 Ϯ 4.8 units postoperative, P ϭ 0.01).
S plenectomy has remained an essential therapeutic intervention for benign hematologic disease, with certain platelet disorders and anemias responding to surgical intervention. The use of splenectomy for the treatment of hematologic malignancies has been more controversial, however, with studies either advocating or discouraging its use in patients with chronic or acute leukemia, lymphoma, or myelodysplastic syndrome (MDS). Early reports that splenectomy carried a higher rate of morbidity and mortality when performed for hematologic malignancy initially made surgery the therapeutic intervention of last resort. [1] [2] [3] More recent studies, however, have shown that splenectomy was safe and had potential therapeutic benefit for certain hematologic malignancies. Specifically, patients with chronic lymphocytic leukemia (CLL) who underwent splenectomy had morbidity and mortality rates comparable to those patients who received only chemotherapy. 4 Furthermore, splenectomized patients with CLL experienced an improvement in certain hematologic parameters after surgery. 4, 5 Similar studies have demonstrated that splenectomy is safe for patients with chronic myelogenous leukemia (CML), even during the blastic or accelerated phase of disease. 6 These patients also experienced hematologic improvements as well as symptomatic relief after splenectomy. 6 Splenectomy has also been performed in patients with lymphoma with minimal morbidity and mortality, to treat symptoms related to splenomegaly or to treat a persistent focus of disease. 3 The potential benefits of splenectomy in patients with hematologic malignancies are many. For patients with symptomatic splenomegaly, splenectomy effectively relieves the associated early satiety, fullness, or pain. Also, when the spleen remains a site of bulky disease, splenectomy may improve the ability to deliver effective chemotherapy. The ability of splenectomy to potentially impact disease-related thrombocytopenia and anemia is of significant importance in the management of the patient with hematologic malignancy. Thrombocytopenia presents one of the more challenging obstacles to optimal treatment and may result in frequent costly transfusions, increased risk of life-threatening hemorrhage, and increased potential exposure to infectious diseases and development of antibodies. It may further limit optimal administration of chemotherapy.
Despite its potential benefits, splenectomy remains an infrequent treatment option in the care of patients with hematologic malignancies. We undertook this study to determine the postsplenectomy platelet kinetics and the impact of splenectomy on transfusion requirements in patients with chronic and acute leukemia, myelodysplastic syndrome, and lymphoma. The effect of splenectomy on those patients with profound thrombocytopenia (preoperative platelet count Ͻ 20,000/L) was further investigated.
MATERIALS AND METHODS
We reviewed the records of all patients with hematologic malignancies who underwent splenectomy from January 1993 until January 2000 at the University of Texas M. D. Anderson Cancer Center (n ϭ 134). Hematologic malignancies, for the purpose of this study, were broadly classified into chronic leukemias: CLL and CML; acute leukemias: acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML); MDS; and lymphoma. Patient-specific data retrieved for analysis included patient age, gender, and specific hematologic diagnosis. Operative data extracted included splenectomy type (open or laparoscopic), splenic weight, and perioperative morbidity and mortality. The perioperative period was defined as the time from splenectomy until 30 days postoperatively. Hematologic values were obtained presplenectomy and up to 5 years postsplenectomy when available. Transfusion requirements were quantified using computerized central blood bank records. Total transfusion requirements for the 3-month period before and the 3-month period after splenectomy were determined, including transfusions given immediately after surgery. Statistical comparisons were performed using the Wilcoxon matched pairs test for continuous hematologic variables and to evaluate transfusion requirements. Results are reported as medians or means Ϯ standard error of the mean, with statistical significance at the P Ͻ 0.05 level.
To objectively evaluate platelet response, we used a classification based on the hematologic response criteria as reported by Thiruvengadam. 7 It is defined as follows: For all patients, no response was experienced if platelets decreased postoperatively or increased by Ͻ 20 K/L; a fair response was experienced if platelets increased by Ͻ 50 K/L; a good response was achieved if platelets increased by Ն50 K/L, but absolute platelet levels was Ͻ 150 K/L; and an excellent response was experienced if platelets increased by Ն50 K/L and absolute platelet count was Ն150 K/L. Median platelet levels were used to assess the postoperative platelet response criteria. A preoperative platelet count of less than 20 K/L was used to define those patients who were considered profoundly thrombocytopenic before splenectomy. The profoundly thrombocytopenic group represents a subset of the entire cohort of splenectomized patients with hematologic malignancy. Information obtained from this subset was analyzed separately as well as part of the entire group.
Our technique for open splenectomy 8 and laparoscopic splenectomy 9 has been described in detail elsewhere. Of significance is that we perform splenic artery ligation as one of the first steps in the operative procedure, regardless of whether splenectomy is laparoscopic or open. Early splenic artery ligation effectively autotransfuses the patient and also allows for administration of platelets without concern about further platelet sequestration. Patients are not routinely transfused platelets; we reserve platelet administration for profoundly thrombocytopenic patients with clinical evidence of bleeding. Patients are not routinely administered the pneumococcal, meningococcal, or Haemophilus influenzae type b vaccines in the pre-or perioperative periods. Vaccinations were left to the discretion of the surgeon or referring oncologist.
RESULTS

Patient Demographics and Perioperative Factors
Splenectomy for hematologic malignancy was performed in 134 patients during the study period of January 1993 until January 2000. Patient demographics and characteristics are detailed in Table 1 . Splenectomy for hematologic malignancy was more common in males than in females. The demographics for the profoundly thrombocytopenic group were similar to those of the entire study group. Specific Annals of Surgery • Volume 240, Number 5, November 2004 Splenectomy in Hematologic Malignancy hematologic diagnoses are detailed in Table 1 . For the entire study group, lymphoma was the most common diagnosis and acute leukemia the least common. For the subgroup of patients with profound thrombocytopenia, the most common diagnosis was CML. The mean postsplenectomy follow-up period was 17.9 Ϯ 1.6 months with a median follow up of 11.3 months. The indications for which patients were referred for splenectomy included thrombocytopenia (n ϭ 71, 54%), splenomegaly (n ϭ 51, 39%), splenectomy for disease diagnosis (n ϭ 7, 5%), and anemia (n ϭ 2, 2%). Although no specific preoperative criteria were applied for determination of eligibility for splenectomy, 106 (79%) patients underwent preoperative megakaryocyte assessment. Megakaryocytes were present in 66 (62%) of assessed bone marrow aspirates. Perioperative factors are shown in Table 2 . Standard open splenectomy was performed in 84% of patients; all patients in the profoundly thrombocytopenic subgroup underwent open procedures. Pathologic evaluation of all specimens revealed a median splenic weight of 1141 g, revealing significant splenomegaly. There were 6 (5%) perioperative deaths in the entire group; 3 of these deaths were in patients with profound thrombocytopenia, making for a 16% mortality rate in this subgroup. The causes of death included pulmonary sepsis with multisystem organ failure (n ϭ 3), cardiogenic shock (n ϭ 1), pulmonary embolus (n ϭ 1), and intracerebral hemorrhage (n ϭ 1). The patient with the intracranial hemorrhage had a preoperative platelet count of 1 K/L. Morbidity was divided into major and minor complications as defined in Table 2 . Morbidity rates were similar between the group as a whole and the profoundly thrombocytopenic subgroup.
Platelet Response
Platelet response to splenectomy for all patients is demonstrated in Figure 1 . The mean preoperative platelet level was 97 Ϯ 8 K/L (median, 82 K/L), demonstrating that preoperative thrombocytopenia was common in patients with hematologic malignancy and splenomegaly. Mean postoperative platelet counts were significantly elevated compared with the preoperative level (P Ͻ 0.05) at each of the evaluated time points. Peak platelet counts were reached on postoperative day 7, with a mean level of 331 Ϯ 30 K/L (median, 260 K/L). Although the number of assessable patients decreased as the postoperative time period increased, platelet levels remained elevated even at 5 years postsplenectomy (mean, 238 Ϯ 44 K/L; median, 240 K/L; P Ͻ 0.05; n ϭ 6). Analysis of the profoundly thrombocytopenic subgroup (n ϭ 19) revealed similar findings (Fig. 2) . The mean preoperative platelet count was 11 Ϯ 1 K/L (median, 13 K/L). Mean postoperative platelet levels were significantly elevated compared with preoperative count (P Ͻ 0.05) at each of the evaluated time points up to 1 year. In fact, the peak platelet level was achieved at 1 year postsplenectomy with a mean value of 137 Ϯ 52 K/L (median, 144 K/L). Statistical comparisons were not feasible after 1 year as a result of the small number of evaluable patients.
Platelet response was also evaluated according to hematologic diagnosis (Fig. 3) . For the purpose of subgroup analysis, CLL and CML were classified as chronic leukemias; ALL and AML were classified as acute leukemias. An increase in platelet levels postoperatively was seen in all subgroups. In the chronic leukemias (P Ͻ 0.01) and lymphoma (P Ͻ 0.001), this increase reached significance at each evaluated time up until 2 years after splenectomy. The post- operative increase in platelets for the MDS patients did not reach statistical significance. Although the evaluated patients with acute leukemias experienced an increase in platelet levels after splenectomy, the small number of patients with acute leukemia who underwent splenectomy made statistical comparisons meaningless (data not shown). It was not feasible to statistically analyze the subgroup platelet response among profoundly thrombocytopenic patients, because the sample size was too small. To better characterize the platelet response, the absolute change in postoperative platelet level was calculated at selected time periods. Table 3 demonstrates that splenectomy provided a durable increase in mean and median platelet levels. Furthermore, we attempted to objectively assess the platelet response an individual patient may experience. A modification of standard platelet response criteria was used to analyze the number of patients who responded to splenectomy and the extent of that response. This platelet response scale is detailed in the "Methods" section. For all time periods analyzed (Table 3 ), 70% to 80% of patients experienced an excellent platelet response. No response was seen in only 10% to 18% of patients. Small sample size precluded subgroup analysis for profoundly thrombocytopenic patients or by hematologic diagnosis.
Platelet Transfusion Requirements
Using computerized blood bank records, the mean units of platelets transfused was determined for the 3-month period before splenectomy and the 3-month postsplenectomy period. For all patients (Fig. 4) , mean platelet transfusion requirements were significantly decreased from the preoperative period (8.6 Ϯ 2 units) compared with the postsplenectomy period (mean, 5.0 Ϯ 1 unit; P ϭ 0.03). Inclusion of patients who did not receive preoperative transfusions in the analysis did not alter the significant decrease in postsplenectomy platelet transfusions. The decrease in postoperative platelet transfusion requirement was even more pronounced in profoundly thrombocytopenic patients (Fig. 5 ). Mean preoperative platelet transfusion requirement was 31.6 Ϯ 10.6 units in this subgroup as compared with the postsplenectomy mean transfusion of 8.9 Ϯ 4.8 units (P ϭ 0.01). 
DISCUSSION
The role of splenectomy in hematologic malignancies has long been debated. Early reports demonstrated hematologic benefit to splenectomy, 10, 11 but other studies revealed high morbidity and mortality rates in this population. [1] [2] [3] Recent advances in surgical technique and perioperative care have made splenectomy much safer, even in the setting of massive splenomegaly 12, 13 and advanced hematologic malignancy. 4, 6 Emerging technology for minimally invasive surgery has made laparoscopic splenectomy a safe and less morbid alternative to open splenectomy in many patients. 9 At the same time, however, advances in chemotherapeutic and molecular targeting of hematologic malignancies have allowed for optimal medical management of these patients, likely decreasing the need for surgical intervention. The emerging role of monoclonal antibody (mAb)-based therapy 14, 15 and signal transduction inhibitors such as the BCR-ABL tyrosine kinase inhibitor STI571 16 will further define what supportive role splenectomy may play in this patient population.
We have previously demonstrated that patients with hematologic malignancies successfully underwent open 8 and laparoscopic 9 splenectomy with acceptable morbidity and mortality rates. We have further shown that for a subgroup of CLL patients, splenectomy improved survival 17 and resulted in a sustained increase in patient platelet levels, 4 including those with thrombocytopenia. 5 Several smaller studies have demonstrated similar hematologic benefit to splenectomy. 18 -20 In CML patients, splenectomy was safely performed and resulted in an increase in platelet level. 6 Improvements in imaging techniques and nonsurgical therapy have diminished the role of splenectomy as a staging tool for Hodgkin lymphoma. In both Hodgkin and non-Hodgkin lymphoma, however, splenectomy has been used to treat symptomatic splenomegaly, splenic sequestration of cells, and to eliminate persistent foci of hematologic disease. 3 In MDS, thrombocytopenia is often of central origin, the result of abnormal bone marrow function. Previous studies have failed to demonstrate significant hematologic benefit to splenectomy. 21 One recent study in MDS patients, however, suggested a potential improvement in platelet level when thrombocytopenia resulted from peripheral platelet destruction. 22 In the present study, we evaluated the postsplenectomy platelet kinetics and the impact of splenectomy on transfusion requirements in patients with chronic and acute leukemias, lymphoma, and myelodysplastic syndrome. During the study period, 134 patients underwent either open or laparoscopic splenectomy for hematologic malignancy. The overwhelming use of open splenectomy is explained by the fact that laparoscopic splenectomy techniques were evolving during the study period. We have reported our results of laparoscopic splenectomy in hematologic malignancy elsewhere and are encouraged by the initial results. 9 In the profoundly thrombocytopenic subgroup, no splenectomies were attempted laparoscopically. This is likely explained by surgeon judgment, defaulting to the open procedure in those patients perceived to be at highest risk.
A perioperative mortality rate of 5% demonstrates that splenectomy can be performed safely in this patient population. Treatment of certain hematologic malignancies with chemotherapy alone carries similar or higher mortality rates. 23 Approximately one third of patients experienced postoperative complications, but the major morbidity rate of only 4% again demonstrates that splenectomy can be safely performed in patients with hematologic malignancies. The 16% mortality rate in the profoundly thrombocytopenic group likely reflects a higher operative risk as a result of the advanced state of disease and underscores the dangers of severe thrombocytopenia. 
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Annals of Surgery • Volume 240, Number 5, November 2004 Changes in mean platelet counts are important for an objective analysis of postsplenectomy platelet kinetics. A more practical analysis, however, should determine the percentage of patients who demonstrate a beneficial platelet response. To accomplish this, we used a modified platelet response criteria, which uses a quantifiable change in platelet level to create a qualitative stratification of platelet response. Overwhelmingly, the group as a whole demonstrated an excellent platelet response at all assessed times after splenectomy. However, the finding of "no platelet response" was more common than a "good" or "fair" platelet improvement. Although a statistical conclusion cannot be drawn from these data, it is interesting that patients had either an "excellent response" (the overwhelming majority) or "no response" with few intermediate improvements. Therefore, when the platelet levels do respond to splenectomy, that response is likely to be an excellent one.
Improvements in platelet levels are extremely important for clinical management. However, an even more compelling argument in favor of splenectomy could be made if it impacted on platelet transfusion requirements. As previously outlined, platelet transfusion carries clinical risk to the patient, is extremely expensive, and uses scarce blood bank, nursing, and hospital resources. The tremendous monetary and resource utilization impact of transfusions is well known. The mean cost of a 2-unit transfusion of packed red blood cells for non-bone marrow transplantation hematologic malignancies was $569 in 1998 dollars 24 and $560 per platelet transfusion in 2000 dollars. 25 These studies further stressed that the personnel time used and physical resources necessary at all steps of the transfusion process were significantly higher than previously analyzed. Importantly, antigenic testing and reliance on single-donor transfusions may further increase these costs. In the present study, we demonstrated a significant decrease in the platelet transfusion requirements for patients with hematologic malignancy who underwent splenectomy. As anticipated, the profoundly thrombocytopenic group required more transfusions overall, but splenectomy dramatically decreased platelet transfusion requirements. Using the cost estimates described here, the 3-month postsplenectomy decrease in transfusion requirements may translate to a savings of approximately $2000 per patient for the group as a whole and approximately $12,000 for the profoundly thrombocytopenic subgroup.
We conclude that in the hematologic malignancies, splenectomy produces a significant and longlasting restoration of platelet levels and a resultant decrease in platelet transfusion requirements in most patients. These beneficial effects of splenectomy hold true even for the most profoundly thrombocytopenic patients. This study provides compelling evidence of a hematologic benefit to splenectomy in certain patients with hematologic malignancy. Although splenectomy may not serve as an independent single-modality therapeutic intervention for patients with hematologic malignan-cies, its role as an adjunct in certain patients with hematologic deficits may be warranted.
